Interleukin-22 , as a link between leukocytic and nonleukocytic cells, has gained increasing attention for its pronounced tissue-protective properties. MicroRNAs, emerging as crucial immune modulators, have been reported to be involved in the production and action of various cytokines. However, the precise control of IL-22 by microRNAs and its subsequent actions remained to be elucidated. In this study, we found a negative correlation between the expression of microRNA 15a/ 16-1 (miR-15a/16-1) and T issue damage is a significant inducer of pathophysiology that determines the course of several diseases.
T issue damage is a significant inducer of pathophysiology that determines the course of several diseases.
(1) Persistent tissue damage increases the risk of carcinoma. Growing evidence suggests that immune-mediated mechanisms play significant roles in tissue repair and regeneration. (2) Indeed, the immune response to tissue injury is crucial in determining the speed and outcome of the repair Abbreviations: AHR, aryl hydrocarbon receptor; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CD, cluster of differentiation; ConA, concanavalin A; DSS, dextran sodium sulfate; FACS, fluorescence-activated cell sorting; IL-22, interleukin-22; IL-22R, IL-22 receptor; KO, knockout; mAb, monoclonal antibody; miR-15a/16-1, mature microRNA 15a/16-1; miRNA, microRNA; NK, natural killer; pSTAT3, phosphorylated STAT3; rIL-22, recombinant IL-22; RORct, retinoid orphan receptor ct; STAT3, signal transducer and activator of transcription 3; Th17, T helper 17; TNF-a, tumor necrosis factor alpha; UTR, untranslated region; WT, wild type.
process, which includes tissue regeneration and the restoration of organ function. Recently, interleukin-22 (IL-22) has generated considerable interest as a promising target in tissue injury. (3) (4) (5) IL-22, also called IL-TIF for "IL-10-related T cellderived inducible factor," has gained increasing attention due to its contributions to epithelial tissue repair and host defense. (6) Initially, IL-22 was viewed as a T helper 17 cell (Th17) cytokine, but subsequent evidence indicated that it can be produced by various cells of the adaptive or innate immune system. Cluster of differentiation 4-positive (CD4 1 ) T cells (Th1, Th17, Th22), CD8
1 T cells, as well as natural killer (NK) cells, NK T cells, innate lymphoid cells, and cd T cells are all able to secrete IL-22; and several of them generate it independently of IL-17.
(7) IL-22 binds to a heterodimeric receptor complex comprised of IL-22 receptor (IL-22R) and IL-10R, in which IL-22R is confined to epithelial cells to exert its function. (8, 9) Subsequent ligation of this receptor complex activates the Janus kinase-signal transducer and activator of transcription 3 (STAT3) signaling pathway. (10, 11) Because of its various roles in different diseases, IL-22 is emerging as an attractive target for clinical therapy. (6) However, the therapeutic options have to be individualized based on organ and/or pathology. Successful implementation of IL-22-associated therapeutic strategies requires better study of the cellular sources and regulatory mechanisms of IL-22 expression.
Recently, growing evidence has identified microRNAs (miRNAs, a group of small noncoding RNAs) as critical posttranscriptional modulators of gene expression that contribute to the production of cytokines and participate in multiple physiological and pathological processes. (12, 13) MiRNA 15b (miR-15b) was reported to suppress the expression of IL-17 and is associated with the pathogenesis of multiple sclerosis, and miR-17-92 regulates IL-10 production and controls experimental autoimmune encephalomyelitis. (14, 15) Furthermore, our previous studies reported that miR-34a and miR-155 regulate the expression of tumor necrosis factor alpha (TNF-a), and IL-6 in murine macrophages by targeting Notch1 and Socs1, respectively, and are involved in lipopolysaccharideinduced acute inflammatory response. (16, 17) However, there is a lack of direct evidence supporting the regulatory relationship between miRNAs and IL-22, and how miRNAs regulate IL-22 production is poorly understood.
The miR-15a/16-1 cluster located at chromosome 13q14 was first identified as a tumor-suppressive miRNA cluster. Accumulating studies have suggested that miR-15a/16-1 acts as a regulator of immune processes, including NK maturation and regulatory T-cell development. (18) (19) (20) Notably, recent studies discovered that deletion of miR-15a/16-1 decreased bacterial infection-associated mortality in sepsis mouse models, which was similar to the role of IL-22 in host defense during various infections. (8, 21) In the present study, we found a negative correlation between miR-15a/16-1 expression and the levels of IL-22 in concanavalin A (ConA)-induced, immune-mediated liver injury, and deficiency of miR-15a/16-1 ameliorated liver injury in an IL-22-dependent manner. Moreover, we demonstrated that deficiency of miR-15a/16-1 increased IL-
production in CD4
1 T cells by promoting the expression of aryl hydrocarbon receptor (AHR). In addition, IL-22 could decrease the expression of miR15a/16-1 by activating phosphorylated STAT3 (pSTAT3)-c-myc signaling to promote tissue repair. Furthermore, we validated the effect of the miR-15a/ 16-1-AHR-IL-22 regulatory axis on dextran sodium sulfate (DSS)-induced colitis to confirm its role in tissue repair. Taken together, these results indicate that miR-15a/16-1 regulates IL-22 production by CD4 1 T cells that promote tissue repair.
Materials and Methods

MICE
C57BL/6 background B6.129S-Mirc30 tm1.1Rdf/J mice containing a LoxP-flanked miR-15a/16-1 allele cluster and B6.C-Tg (CMV-cre) 1Cgn/J mice were purchased from the Jackson Laboratory (Bar Harbor, ME). The two kinds of mice were interbred to generate miR-15a/16-1 gene knockout (miR-15a/16-1 KO) mice. Wild-type (WT) C57BL/6 mice at 6-8 weeks of age were obtained from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). B6.129S7-Rag1 tm1Mom /J (Rag-1 -/-) mice on a C57BL/6 background were purchased from Peking University ShenZhen Hospital (Shenzhen, China). All of the mice used for experiments were raised in the animal facility of Fudan University (Shanghai, China) under specific pathogen-free barrier conditions. All animal experiments were performed according to the Guidelines for the Care and Use of Laboratory Animals.
MOUSE MODEL
Pathogen-free 8-week-old male WT mice were injected intravenously with ConA (Sigma-Aldrich, St. Louis, MO) at a dose of 15 lg/g body weight to induce acute liver injury. (22) Mice were sacrificed at 0, 1, 3, 6, and 9 hours postinjection. In some experiments, miR15a/16-1 KO mice were injected intravenously with 15 lg/g ConA, and an IL-22 neutralizing monoclonal antibody (IL-22mAb) at a dose of 2.5 lg/g or isotypematched mAb was injected intravenously 30 minutes later. Mice were sacrificed 9 hours after ConA injection. The liver was removed for histological analysis. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured with the ALT and AST Activity Assay Kit (Elabscience, Wuhan, China). 
OVEREXPRESSION OF miR
TRANSFECTION OF SMALL INTERFERING RNAs
Small interfering RNAs were transfected into AML-12 cells using Lipofectamine 2000 Transfection Reagent (ThermoFisher; 11668030) according to the manufacturer's protocol. Cells were seeded to 30%-50% confluence at transfection. Then, diluted DNA and diluted Lipofectamine 2000 reagent were incubated for 20 minutes at a 1:1 ratio. Finally, a DNAlipid complex was added to the cells. Small interfering RNAs of c-myc were purchased from Biotend.
T-CELL TRANSFER AND COLITIS INDUCTION
Sorted splenic CD4
1 T cells from C57BL/6 or miR-15a/16-1 KO mice were transferred intravenously (1 3 10 7 cells/mouse) into Rag-1 -/-mice. Forty-eight hours post-T-cell transfer, liver injury or colitis was induced in Rag-1 -/-mice. Liver injury was induced as mentioned above, and colitis was induced by DSS (MP Biomedicals, Santa Ana, CA). Mice were given 2% DSS in their drinking water for 6 days, followed by regular drinking water, and weight was monitored daily. Mice were killed, and the colons were removed for histological analysis or cell isolation 8 days after the initiation of DSS treatment.
ANTIBODIES AND FLUORESCENCE-ACTIVATED CELL SORTING ANALYSIS
Antibodies against CD45, CD3e, T-cell receptor a, CD4, CD8a, NK1.1, IL-22, IL-17A, and AHR (all from eBioscience, San Diego, CA) were used for flow cytometry. Surface staining was performed following the manufacturer's instructions. For intracellular staining of IL-22, IL-17A, and AHR, cells were stimulated in vitro with a cocktail containing phorbol 12-myristate 13-acetate, ionomycin, brefeldin A, and monensin (eBioscience) for 5 hours before fluorescence-activated cell sorting (FACS) analysis. The data were acquired by a CyAn ADP Analyzer (Beckman, Coulter) and analyzed using Flowjo software (Tree Star, Ashland, OR).
LUCIFERASE REPORTER ASSAY
AHR mRNA 3 0 -untranslated region (3 0 -UTR) fragments (NM-013464) containing the putative miR15a/16-1 binding sequence were amplified by PCR and cloned between XbaI and FseI cutting sites of the pGL3-control vector (Promega; E1741) downstream of the luciferase reporter gene. Restriction endonucleases XbaI (New England Biolabs; R0145) and FseI (New England Biolabs; R0588) and the Rapid DNA Ligation Kit (Roche; 11635379001) were used. DNA sequencing was performed to validate the PGL3-con-AHR-UTR vectors. The primers used for the AHR-3 0 -UTR clones are listed in Supporting Table S1 . AML-12 cells (ATCC; CRL-2254) were cultured according to the culture methods. Cell extracts were prepared 24 hours after transfection, and luciferase activity was measured with the Dual-Luciferase Reporter Assay system according to the manufacturer's protocols (Dual-Glo Luciferase Assay System; Promega; E2920).
NAIVE T-CELL ISOLATION AND STIMULATION
Naive CD4 1 T cells were purified by magneticactivated cell sorting (Miltenyi; 130-104-453), and the purity was >95% as judged by FACS. In vitro, naive CD4
1 T cells were stimulated with ConA (Sigma; C0142, 2 mg/mL) in the presence of IL-6 (R&D; 406-ML-005, 10 ng/mL) and TNF-a (R&D, 410-MT-010, 5 ng/mL) to promote production of IL-22. After 48 hours, supernatants and cells were harvested for measurement of IL-22 production by enzymelinked immunosorbent assay and FACS, respectively.
STATISTICAL ANALYSIS
An unpaired t test was applied for statistical comparison between two independent groups. Analysis of variance was used to analyze more than two groups. Pearson's correlation coefficient was used for correlation analysis between groups. Survival was analyzed by the Kaplan-Meier method and compared by the logrank test. All data were analyzed by GraphPad Prism 5 and presented as means 6 SEM. P < 0.05 was considered statistically significant.
Results
DEFICIENCY OF miR-15a/16-1 AMELIORATES ConA-INDUCED LIVER INJURY BY INCREASING THE PRODUCTION OF IL-22
Given that the contribution of IL-22 to tissue repair is widely accepted, we constructed the ConA-induced experimental model of T cell-mediated liver injury to explore the regulatory mechanisms of IL-22. We found that mRNA expression of IL-22 was significantly increased in the livers after injection of ConA as reported, while mRNA expression of miR-15a/16-1 was remarkably decreased, which displayed a negative correlation between miR-15a/16-1 and IL-22 (Fig.  1A) . To determine whether miR-15a/16-1 influences IL-22 expression and IL-22-mediated tissue repair, 15 lg/g ConA was injected into miR-15a/16-1 KO mice and WT mice. IL-22 expression and subsequent liver injury were analyzed 9 hours after ConA injection. The results showed that both the mRNA and protein levels of IL-22 were up-regulated in the livers of miR-15a/16-1 KO mice compared with WT mice ( Fig. 1B; Supporting Fig. S1 ) and that the expression of IL-22R was higher in the livers of miR-15a/16-1 KO mice than in WT mice (Fig. 1C) . Moreover, miR-15a/16-1 KO mice displayed remission of liver injury, with decreased elevation in ALT and AST and spotted necrosis in the livers, while increased elevation in ALT and AST and massive necrosis were induced after up-regulation of miR-15a/16-1 in vivo ( The results showed that neutralization of IL-22 in miR-15a/16-1 KO mice markedly enhanced ALT and AST levels and induced more severe liver damage compared with miR-15a/16-1 KO mice (Fig.  1D,E) . Consistently, mRNA expression of antiapoptotic proteins (Bcl-2, Bcl-xL) was increased in the livers of miR-15a/16-1 KO mice compared with WT mice after ConA injection, while anti-IL-22 treatment almost completely prevented the increase of Bcl-2 and Bcl-xL (Fig. 1F) . These results suggest that deficiency of miR-15a/16-1 attenuates ConAinduced liver injury by promoting the production of IL-22.
DEFICIENCY OF miR-15a/16-1 INCREASES THE PRODUCTION OF IL-22 IN CD4
1 T CELLS
To clarify the cellular source of IL-22 that was affected by miR-15a/16-1 in ConA-induced liver injury, we detected the production of IL-22 in CD3 . WT mice treated with phosphate-buffered saline served as controls. The data are pooled from three independent experiments, each with three or four mice and are expressed as means 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: PBS, phosphate-buffered saline; PI, propidium iodide; TUNEL, terminal deoxynucleotide transferase-mediated deoxyuridine triphosphate nick end-labeling.
ConA-induced liver injury ( Fig. 2A) , and doubleimmunostaining demonstrated that IL-22 1 cells were most positive for CD4 (Supporting Fig. S3A) Fig. S3B ). In contrast to the increased expression of IL-22, the levels of miR-15a and miR-16-1 in CD4
1 T cells in the livers of ConA-administered WT mice (Supporting Fig. S3C ), as well as in the CD4 1 T cells stimulated with ConA (2 lg/mL) in vitro, were decreased (Supporting Fig.  S3D ). More importantly, CD4
1 T cells from the spleens and livers of ConA-administered miR-15a/16-1 KO mice demonstrated more IL-22 secretion than those of WT mice (Fig. 2B) , which implies that miR-15a/16-1 may affect the IL-22 secretion of CD4 1 T cells. Given that IL-6 has been reported to trigger the production of IL-22 in naive CD4 1 T cells alone or in combination with TNF-a and that evidence in humans indicates that IL-6 and TNF-a promote the generation of IL-22-secreting T cells (Th22), we further 1 T cells from the spleens of WT mice and miR-15a/16-1 KO mice were stimulated with ConA (2 lg/mL) combined with TNF-a (5 ng/mL) and IL-6 (10 ng/mL) for 48 hours. Expression of IL-22 was detected by quantitative PCR, enzyme-linked immunosorbent assay, and FACS. (E,F) Naive CD4 1 T cells were activated by ConA (2 lg/mL) combined with TNF-a (5 ng/mL) and IL-6 (10 ng/mL) for 48 hours after transfection with miR-15a and miR-16-1 mimics or control. Expression of IL-22 was detected by quantitative PCR, enzyme-linked immunosorbent assay, and FACS. The data shown are the means 6 SEM from one experiment that was repeated three times, yielding similar results. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: NC, negative control; PBS, phosphate-buffered saline.
confirmed the effect of miR-15a/16-1 on IL-22 production in CD4
1 T cells under stimulation of IL-6 and TNF-a in vitro. Naive CD4 1 T cells were isolated from the spleens of WT and miR-15a/16 KO mice and stimulated with ConA in the presence of IL-6 and TNF-a. After 48 hours, mRNA expression and production of IL-22 were assessed. The results showed that activation of naive CD4
1 T cells with ConA in the presence of IL-6 and TNF-a resulted in higher production of IL-22 (Supporting Fig. S3E ) and that deficiency of miR-15a/16-1 in CD4
1 T cells facilitated the increase of IL-22 at both the mRNA and protein levels (Fig. 2C,D) . Congruently, miR-15a/16-1 mimics were used to up-regulate the endogenous levels of miR-15a/16-1 in naive CD4
1 T cells (Supporting Fig. S3F) . A significant decrease of IL-22 was detected in miR-15a/16-overexpressing CD4
1 T cells at both the mRNA and protein levels (Fig. 2E,F) . Taken together, these results indicate that miR-15a/ 16-1 regulates IL-22 production in CD4 1 T cells.
AHR IS REQUIRED FOR THE miR-15a/16-1-DEPENDENT REGULATION OF IL-22 PRODUCTION IN CD4 1 T CELLS
Subsequently, we investigated the mechanisms underlying the modulation of miR-15a/16-1 on IL-22 production by CD4 1 T cells. Increased cell number and proliferation were considered potential reasons for the up-regulation of IL-22 in miR-15a/16-1 KO CD4 1 T cells. However, in vivo data showed that the percentages of CD4 1 T cells in the livers of miR-15a/ 16-1 KO mice did not increase but slightly decreased, and it did not change in the spleens compared with WT mice 9 hours after ConA injection (Supporting Fig. S4A ). Consistently, in vitro, miR-15a/16-1 deletion did not affect the proliferation of CD4 1 T cells (Supporting Fig. S4B ). Next, we detected the representative transcription factors that have been reported to be crucial for IL-22 production, such as AHR, retinoid orphan receptor ct (RORct, RORC), and STAT3. We found that the mRNA expression of AHR in the livers of ConA-administered miR-15a/ 16-1 KO mice was higher than that in ConAadministered WT mice (Fig. 3A) . Moreover, the upregulation of AHR in the livers of ConA-administered miR-15a/16-1 KO mice was also confirmed at the protein level by western blot (Fig. 3B) . Furthermore, CD4
1 T cells in the spleens and livers of ConAadministered miR-15a/16-1 KO mice increased the expression of AHR compared with those of ConAadministered WT mice (Fig. 3C) .
In addition, we isolated naive CD4 1 T cells from the spleens of WT and miR-15a/16-1 KO mice and stimulated them with ConA in vitro in the presence of IL-6 and TNF-a. As the data show, deficiency of miR-15a/16-1 in naive CD4
1 T cells increased the expression of AHR at both the mRNA and protein levels (Fig. 3D) . Consistently, overexpression of miR-15a/ 16-1 in naive CD4
1 T cells dramatically decreased both the mRNA and protein levels of AHR (Fig. 3E) . Moreover, the AHR-specific antagonist CH-223191 reversed the increase of IL-22 production trigged by miR-15a/16-1 deficiency (Supporting Fig. S5A ). Overexpression of miR-15a/16-1 no longer inhibited IL-22 production in naive CD4
1 T cells upon use of the AHR agonist 6-formylindolo[3,2-b] carbazole (Supporting Fig. S5B ). To identify whether AHR was a target of miR-15a/16-1 in CD4
1 T cells, a dual-luciferase reporter plasmid containing the 3 0 -UTR of AHR mRNA was constructed. The results from the luciferase assay showed that AHR had a direct binding site for miR-15a/16-1 in the 3 0 -UTR (Fig. 3F ). These data demonstrate that AHR is a direct target of miR-15a/ 16-1 and is responsible for the modulation of miR-15a/ 16-1 on the production of IL-22 in CD4 1 T cells.
ADOPTIVE TRANSFER OF miR-15a/16-1 KO CD4 1 T CELLS ALLEVIATES ConA-INDUCED LIVER INJURY
To further confirm that the regulation of miR-15a/ 16-1 on IL-22 production in CD4 1 T cells was essential for controlling ConA-induced liver injury and the subsequent liver repair, miR-15a/16-1 KO CD4 1 T cells or WT CD4
1 T cells were transferred into Rag-1 -/-mice, followed by ConA injection. AHR expression in the livers of Rag-1 -/-mice transferred with miR-15a/ 16-1 KO CD4 1 T cells was higher than that of mice transferred with WT CD4 1 T cells ( Fig. 4A ; Supporting Fig. S6A ). Moreover, higher expression of AHR was detected in the transferred miR-15a/16-1 KO CD4
1 T cells in both the spleens and livers compared with the WT CD4 1 T cells (Fig. 4A ). In addition, double immunofluorescence showed that transferred miR-15A/16-1 KO CD4
1 T cells were more positive for AHR than WT CD4 1 T cells (Supporting Fig.  S6B ). In accordance with our expectation, Rag-1 -/-mice that received miR-15a/16-1 KO CD4
1 T cells had increased IL-22 at both the mRNA and protein levels (Fig. 4B,C) . Moreover, transfer of miR-15a/16-1 KO CD4
1 T cells ameliorated the liver damage, with sporadic necrosis and decreased ALT and AST compared with the transfer of WT CD4 1 T cells (Fig. 4D-F) . Thus, consistent with our findings in vitro, the in vivo data indicated that deficiency of miR-15a/16-1 increased IL-22 production of CD4 1 T cells by upregulating AHR, subsequently relieving ConA-induced liver injury. All of the data above imply that miR-15a/ 16-1 is essential for the production of IL-22 by CD4 1 T cells from WT mice were activated by ConA (2 lg/mL) combined with TNF-a (5 ng/mL) and IL-6 (10 ng/mL) for 48 hours after transfection with miR-15a and miR-16-1 mimics or control. Expression of AHR was detected by quantitative PCR and FACS. (F) Sequences of target sites for miR-15a and miR-16-1 in the AHR 3 0 -UTR are shown. Luciferase reporter assays were used to identify the binding sites of miR-15a and miR-16-1 to the AHR 3 0 -UTR. The data shown are means 6 SEM from one experiment that was repeated three times, yielding similar results. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: NC, negative control; PBS, phosphate-buffered saline. 3100, 3 200) . The data shown are the means 6 SEM from one experiment, each with four mice, that was repeated twice with similar results. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: HPF, high-power field; IOD, i ntegral optical density; PI, propidium iodide; TUNEL, terminal deoxynucleotide transferase-mediated deoxyuridine triphosphate nick end-labeling. and reducing cell apoptosis; meanwhile, miR-15a/16-1 was dramatically decreased (Fig. 5A,B; Supporting Fig.  S7A ). In contrast, overexpression of miR-15a/16-1 inhibited the increased proliferation of AML-12 induced by IL-22 (Fig. 5B) . To clarify how IL-22 induced the decreased miR-15a/16-1 in AML-12 cells, a panel of factors that were reported to regulate expression of miR15a/16-1 was examined, including c-myc, Dicer, Drosha, and MDM2. The results showed that c-myc was increased after rIL-22 administration, which was accompanied by stronger phosphorylation of STAT3 and the up-regulation of antiapoptotic proteins (Bcl-2, Bcl-xL) ( Fig. 5C; Supporting Fig. S7B) . To confirm the effect of pSTAT3 and c-myc on the IL-22-induced decrease of miR-15a/16-1, an inhibitor of pSTAT3 (AG490) and small interfering RNA of c-myc were used prior to rIL-22 treatment to down-regulate STAT3 signaling and c-myc expression in AML-12 cells (Supporting Fig.  S7C ). The results showed that both inhibition of STAT3 and interference of c-myc reversed the IL-22-induced decrease of miR-15a/16-1 (Fig. 5D,E) . We confirmed the protein levels of pSTAT3, c-myc, Bcl-2, and Bcl-xL in ConA-administered mice (Fig. 5F ). These results indicate that IL-22 contributes to tissue repair by decreasing the expression of miR-15a/16-1 in a pSTAT3-c-myc-dependent manner. The data in (A-D) are pooled from two independent experiments, each with four mice, and are expressed as the means 6 SEM. The data in (E) represent three independent experiments and are expressed as the means 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: LPL, lamina propria lymphocyte; IEL, intraepithelial lymphocyte; NC, negative control.
induced by DSS treatment. We observed remission of DSS-induced colitis in Rag-1 -/-mice transferred with miR-15a/16-1 KO CD4
1 T cells, with increased survival, decreased weight loss, and colon elongation (Fig.  6A) . Histologically, acute colitis in Rag-1 -/-mice was characterized by epithelial damage, focal crypt injury, goblet cell depletion, and inflammatory cell invasion. Adoptive transfer of miR-15a/16-1 KO CD4
1 T cells reduced the histological score compared with transfer of WT CD4
1 T cells (Fig. 6B) . To investigate the impact of the miR-15a/16-1-AHR-IL-22 axis on CD4
1 T cells during DSS-induced colitis, we analyzed IL-22 production and AHR expression in the adoptively transferred mice. We found an increase in the production of IL-22 in the colons of mice transferred with miR-15a/16-1 KO CD4 + T cells (Fig.  6C) . Moreover, the adoptive transfer of miR-15a/16-1 KO CD4
1 T cells into Rag-1 -/-mice resulted in increased IL-22 production and AHR expression in colon tissues and spleens compared with the transfer of WT CD4
1 T cells (Fig. 6C,D) . Furthermore, using the colorectal cancer cell line CT-26, we also observed down-regulation of miR-15a/16-1 after treatment with rIL-22. IL-22 increased the proliferation of CT-26, and overexpression of miR-15a/16-1 reversed the increased proliferation (Fig. 6E) . These data provide evidence for the significant regulatory role of the miR15a/16-1-AHR-IL-22 axis in tissue repair (Fig. 6F) .
Discussion
Various preclinical studies have emphasized the broad therapeutic potential of rIL-22 in epithelial injury, such as in the liver and colon. (3, 4, 23) Thus, research on the regulatory mechanisms underlying the production of IL-22 during various tissue injuries and their subsequent protective actions is crucial. In this study, we provide evidence that miR-15a/16-1 acts as an essential regulator of IL-22 and that the miR-15a/ 16-1-AHR-IL-22 regulatory axis plays a central role in tissue repair. As the data show, CD4
1 T cells were the major cellular source of IL-22 production in ConA-induced liver injury and miR-15a/16-1 KO CD4
1 T cells secrete IL-22 more potently. Moreover, transfer of miR-15a/16-1 KO CD4
1 T cells resulted in promotion of tissue repair in both the liver and colon. In this process, we identified AHR as a direct target of miR-15a/16-1 in CD4 1 T cells. We also demonstrated that, as a synergistic effect, IL-22 could down-regulate the expression of miR-15a/16-1 in damaged hepatocytes by activating pSTAT3-c-myc signaling and that the decrease of miR-15a/16-1 contributed to IL-22-mediated tissue repair. Therefore, modulation of miR-15a/16-1 may hold promise in developing new strategies to enhance IL-22-mediated tissue repair.
The regulation of IL-22 production has been reported in several studies. (24, 25) However, the roles of noncoding RNAs in the regulation of IL-22 production are poorly understood. In the present study, we identified miR-15a/16-1, a small noncoding RNA cluster, as a regulator of IL-22. Previous studies on miR-15a/16-1 focused on its roles in tumors and identified it as a tumor suppressor in many cancers. (26) Notably, recent studies have shown that miR-15a/16-1 also acts as an immune regulator in physiological and inflammatory conditions, impacting macrophage phagocytosis, NK maturation, and T-cell activation. (19, 20) In this study, we explored the role of miR15a/16-1 in T cell-related tissue injury and found that deficiency of miR-15a/16-1 in CD4
1 T cells increased the production of IL-22, which played protective roles in both hepatitis and colitis-associated tissue damage. Our study presents evidence that miR-15a/16-1 functions as a regulator of immune-mediated tissue repair, which extends our knowledge of miR-15a/16-1.
IL-22 was first identified as a cytokine of Th17 cells because it is similar to IL-17A in several aspects. (27) Common factors, such as STAT3, RORct, and AHR, promoted the expression of both cytokines. (28) Both IL-22 and IL-17A were reported to be involved in ConA-induced liver injury. (29, 30) In our study, IL-22 and IL-17A were increased in ConA-induced liver injury; however, ConA-administered miR-15a/16-1 KO mice had a higher expression of IL-22 but a lower expression of IL-17A compared to ConAadministered WT mice. As reported, in human Th22 cells, down-regulation of either AHR or RORct affects IL-22 production, whereas IL-17A production is only affected by down-regulation of RORct. (31) Moreover, Ramirez et al. found that activation of AHR revealed distinct requirements for IL-22 and IL-17A production by human T helper cells. (32) In this study, ConA administration did not affect the expression of RORct in either WT or miR-15a/16-1 KO mice (Fig. 3A) . In addition, deficiency of miR-15a/16-1 did not affect RORct expression in CD4 1 T cells (data not shown). In contrast, AHR expression in CD4 1 T cells from the spleens and livers of miR-15a/16-1 KO mice was higher than that in WT mice. We considered that deficiency of miR-15a/16-1 increased AHR expression, which promoted IL-22 production and had no effects on IL-17A.
Th22 cells abundantly produce IL-22 and are distinct from Th17, Th1, and Th2 cells. (33) Differentiation of the Th22 subsets was efficiently induced in human naive T cells in an IL-6-and TNF-adependent manner. (34) Although it has been difficult to identify the murine counterpart of this population, IL-6 and TNF-a induced higher production of IL-22 and lower production of IL-17A compared to other stimulation methods (Supporting Fig. S3E ). However, expression of IL-6 and TNF-a was decreased in ConA-administered miR-15a/16-1 KO mice (Supporting Fig. S1 ). We supposed that relief of liver injury gave rise to decreased IL-17A, IL-6, and TNF-a.
IL-22 exerts its function by binding to a heterodimer containing IL-22R and IL-10R. IL-22 activates STAT3 signaling, which results in a subsequent increase of antiapoptotic proteins, such as Bcl-xL and Bcl-2. (9, 35) In this study, we found that IL-22 could also reduce the expression of miR-15a/16-1 in both hepatocytes and the colonic epithelia through STAT3 phosphorylation. The inhibition of STAT3 phosphorylation decreased the expression of c-myc, which suppressed miR-15a/16-1 expression through the recruitment of histone deacetylase 3. (35, 36) Bcl-2 was found to be a direct target of miR-15a/16-1. (26) Down-regulation of miR-15a/16-1 contributed to IL-22-mediated tissue repair. We provide an alternative pathway of IL-22 contributing to tissue repair. Signaling upstream and downstream of IL-22 produces synergistic effects on tissue repair.
Collectively, our data reveal that miR-15a/16-1 functions in cancer and also regulates immunemediated diseases. Although IL-22 is regarded as a potential therapeutic target of tissue injury, it has several side effects. Therefore, precise control of IL-22 production is critical to exert its protective function. This study suggests that miR-15a/16-1 acts as a regulator of IL-22 and may represent a novel therapeutic intervention in tissue injury.
